How Does Oestrogel Work in the Body

Chemical Composition, Mechanism of Action & Metabolic Effects Explained

Key Takeaways: How Oestrogel Works

  • Active Ingredient: Estradiol hemihydrate (750 micrograms per pump), identical to natural ovarian estradiol.
  • Transdermal Delivery: Bypasses first‑pass liver metabolism, providing steady hormone levels.
  • Mechanism: Estradiol binds to nuclear estrogen receptors, regulating gene expression to relieve hot flushes, prevent bone loss, and restore urogenital health.
  • Absorption & Duration: Peak serum levels 2–6 hours after application; once‑daily dosing maintains therapeutic levels.
  • Metabolism: Converted in liver to weaker estrogens (estrone, estriol) and excreted via urine.

Oestrogel is a transdermal hormone replacement therapy (HRT) that delivers bio‑identical estradiol directly through the skin. It effectively replenishes declining oestrogen levels during menopause, alleviating symptoms and protecting against osteoporosis without subjecting the liver to high first‑pass concentrations.

Important Medical Advice

Do not use Oestrogel if you have or have had breast cancer, endometrial cancer, unexplained vaginal bleeding, liver disease, or a history of blood clots. Stop use and seek immediate medical help if you develop signs of a blood clot (painful leg swelling, sudden chest pain, difficulty breathing), jaundice, severe headache, or if you become pregnant. Always cover the application site after drying to prevent accidental transfer to children or partners.

Chemical Composition & Formulation

Oestrogel Pump‑Pack 750 micrograms/actuation gel contains estradiol hemihydrate as the active pharmaceutical ingredient. Estradiol is the most potent and predominant human estrogen, chemically identical to that produced by the ovaries before menopause.

Structural & Formulation Details

Estradiol hemihydrate

Estra‑1,3,5(10)‑triene‑3,17β‑diol

Molecular weight 272.4 g/mol; the hemihydrate form enhances stability. Each 1.25 g of gel delivers 750 µg of estradiol, providing precise dosing.

Excipients

Carbomer: A gelling agent that provides the desired viscosity.
Trolamine: pH adjuster to ensure skin compatibility.
Ethanol (0.5 g per dose): Acts as a penetration enhancer, evaporating quickly to facilitate transdermal absorption.
Purified water: Solvent base.

The formulation is alcohol‑based, non‑greasy, and dries within 5 minutes, minimising clothing transfer. The pump delivers a consistent metered dose, ensuring reproducibility.

🗒️ Pharmaceutical insight: The ethanol content aids transdermal delivery by temporarily disrupting the stratum corneum lipid matrix, allowing estradiol to diffuse through the skin barrier efficiently.

Mechanism of Action: Estrogen Replacement Therapy

Oestrogel restores systemic estradiol levels to premenopausal concentrations, thereby activating estrogen receptors (ERα and ERβ) in target tissues. The mechanism is both genomic and non‑genomic:

  1. Genomic pathway: Estradiol diffuses into the cytoplasm, binds to estrogen receptors, and the complex translocates to the nucleus. It then binds to estrogen response elements (EREs) on DNA, regulating transcription of genes involved in vasomotor stability, bone remodelling, and urogenital integrity.
  2. Non‑genomic actions: Rapid membrane‑associated signalling (e.g., through GPER) modulates ion channels and nitric oxide production, contributing to vasodilation and immediate symptom relief.
Target TissueClinical Effect
HypothalamusStabilises thermoregulatory centre, reducing hot flushes and night sweats
BoneInhibits osteoclast activity, preserving bone mineral density and reducing fracture risk
Urogenital tractMaintains vaginal epithelial thickness, pH, and lubrication; reduces dyspareunia and urinary urgency
Cardiovascular systemImproves lipid profile (increases HDL, lowers LDL) and endothelial function

Because Oestrogel is applied transdermally, it avoids the first‑pass hepatic metabolism that occurs with oral oestrogens. This results in a more physiological oestradiol:estrone ratio (~1:1) and reduces the impact on hepatic proteins (e.g., sex hormone binding globulin, clotting factors).

Absorption & Distribution (Pharmacokinetics)

After application to clean, intact skin, the ethanol vehicle evaporates, creating a supersaturated state of estradiol in the stratum corneum. Passive diffusion then occurs across the viable epidermis into the dermal capillary network.

Absorption Rate & Bioavailability

Peak serum estradiol concentrations (Cmax) of 20–80 pg/mL are achieved 2–6 hours post‑application. Steady state is reached after 2–3 days of once‑daily use. Systemic bioavailability via the transdermal route is approximately 5–10%, but because it bypasses liver metabolism, the delivered dose is highly efficient.

Distribution

Estradiol is highly protein‑bound (≈98%), mainly to albumin and sex hormone binding globulin (SHBG). The volume of distribution is large (≈1.2 L/kg). Transdermal application produces relatively stable serum levels without the peaks and troughs seen with oral administration.

Application site matters: the upper arms/shoulders and inner thighs have been shown to provide comparable absorption. Avoiding areas with excessive hair or skin damage ensures consistent uptake.

Metabolic Pathway & Elimination

Once estradiol enters the systemic circulation, it undergoes biotransformation primarily in the liver. The key metabolic steps are:

  • Oxidation: 17β‑hydroxysteroid dehydrogenase converts estradiol to the less potent estrone.
  • Further hydroxylation: CYP3A4 and other cytochrome P450 enzymes convert estrone to estriol and various catechol estrogens.
  • Conjugation: All metabolites are rapidly conjugated with glucuronic acid and sulfate to form water‑soluble compounds.

The elimination half‑life of transdermal estradiol is approximately 12–20 hours. Conjugated metabolites are excreted primarily in urine (≈60%) and faeces (≈40%). Because the gel avoids first‑pass metabolism, hepatic burden is lower compared to oral oestrogens, making it a preferred option for women with mild hepatic impairment or those requiring a more physiological profile.

⚠️ Metabolic caution: Severe liver disease can alter estradiol clearance. Regular monitoring is advised for women with hepatic dysfunction. Additionally, concurrent use of CYP3A4 inducers (e.g., rifampicin, St. John’s Wort) may reduce efficacy.

Clinical Efficacy in Menopause Symptoms & Osteoporosis

Oestrogel is indicated for the relief of moderate to severe vasomotor symptoms associated with menopause and for the prevention of postmenopausal osteoporosis in women at high risk of fractures who cannot take non‑oestrogen medicines.

  • Hot flushes: Clinical studies demonstrate a 80–90% reduction in frequency and severity within 4 weeks of starting therapy.
  • Bone mineral density: Over 2 years, transdermal estradiol preserves lumbar spine and femoral neck BMD, reducing fracture risk by 30–50%.
  • Urogenital health: Vaginal atrophy symptoms (dryness, dyspareunia) improve significantly, often within 2–3 months.

In women with an intact uterus, a progestogen must be added for at least 12 days per cycle to prevent endometrial hyperplasia. The SMART regimen (continuous combined with a progestogen) can also be used after appropriate assessment.

The benefits of Oestrogel outweigh risks for most women when initiated within 10 years of menopause. Treatment duration should be individualised, with annual review of risks and benefits.

Oestrogel FAQs

Many women notice improvement in hot flushes within the first 2 weeks. Full relief of vasomotor symptoms usually occurs after 4–8 weeks of consistent daily use.

Yes, accidental transfer can occur. After the gel dries (about 5 minutes), cover the application site with clothing. If transfer happens, wash the affected skin immediately with soap and water.

If you have a uterus, yes – a progestogen must be taken for at least 12 days per 28‑day cycle to prevent endometrial hyperplasia. Women who have had a hysterectomy can use oestrogen alone.

Common side effects include breast tenderness, nausea, abdominal pain, headaches, and irregular bleeding during the first few months. These usually subside as your body adjusts.

Oestrogel is contraindicated in women with a current or past history of venous thromboembolism. Your doctor will evaluate your individual risk factors before prescribing any HRT.

Need Oestrogel with Expert Guidance?

If you are experiencing troublesome menopausal symptoms and would like to discuss whether Oestrogel is right for you, our UK‑registered doctors can help.

Secure Prescription & Next‑Day Delivery

MHRA‑compliant | GPhC‑registered pharmacy | Discreet packaging | Personalised care

Start Menopause Consultation
Nabeel M. - Medical Content Manager at Chemist Doctor
Authored byNabeel M.

Medical Content Manager

Nabeel is a co-founder, and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.

Medical Doctor

Dr. Feroz is a GMC-registered doctor and a medical reviewer at Chemist Doctor. He oversees acute condition and urgent care guidance.

Usman Mir - Superintendent Pharmacist
Approved byUsman Mir

Medical Director

Usman is a co-founder, and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.

Review Date: 27 March 2026

Next Review: 27 September 2026

Published on: 27 March 2026

Last Updated: 27 March 2026